NCT04138212View on ClinicalTrials.gov

Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903)

PHASE3RecruitingINTERVENTIONAL
Enrollment

456

Participants

Timeline

Start Date

October 22, 2019

Primary Completion Date

December 21, 2023

Study Completion Date

December 21, 2028

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Paclitaxel, Cisplatin

Paclitaxel 175mg/m2 plus Cisplatin 75mg/m2, q21d, 2 cycles

RADIATION

neoadjuvant chemoradiation therapy

Paclitaxel 50mg/m2 plus Carboplatin AUC=2, q1w, 5 cycles; 41.4Gy, 1.8Gy/d\*23

Trial Locations (1)

450008

RECRUITING

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors
lead

Henan Cancer Hospital

OTHER_GOV